Tempus to acquire Personalis for $16.25/share, $1.5B enterprise value

Personalis, Inc.

Consideration of $16.25 per share, 6% premium to last close, 28% premium to 30-day VWAP.
Total enterprise value of $1.5B net of Tempus' existing ownership; 100% stock with cash option up to 50%.
Closing expected late 2026 or early 2027; subject to Personalis shareholder and regulatory approvals.
Personalis reports preliminary Q2 revenue of $22.4M and 10,384 clinical tests, up 33% QoQ.
Acquisition combines Personalis' MRD technology with Tempus' AI platform; MRD market opportunity $20B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.